Production of fission 131I

Siri, Sandra; Mondino, A. V.

doi:10.1007/s10967-005-0910-7

Cited by 6 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since technetium-99 m continues to be the most popular radioisotope for use in nuclear medicine it is not surprising that papers continue to proliferate describing the purification of the parent isotope, molybdenum-99, from fission material, [41][42][43] and to describe new generators [44][45][46] for the elution of technetium from adsorbed molybdenum compounds. A novel column has been described 47 for the elution of indium-111 from tin-111 (t 1/2 = 35 m).…”

Section: Radionuclide Productionmentioning

confidence: 99%

Radiochemistry and radiopharmaceuticals

Urch

Welch

2006

Annu. Rep. Prog. Chem., Sect. A: Inorg. Chem.

View full text Add to dashboard Cite

Following last year's precedent this section of Annual Reports will review not only recent progress in radiochemistry, including isotope production and environmental aspects, but also in the production of radiopharmaceuticals and their use in nuclear medicine for imaging. Radiation chemistry (unless related to the stability of labelled molecules), the use of nuclear activation analysis and the inorganic chemistry of elements that are by their nature, radioactive are all excluded. HighlightsThe IAEA published 1 the results of a wide ranging review of nuclear measurements. Conferences held during 2005 which covered progress in radiochemistry, included the '4th all Polish Conference on Radiochemistry and Nuclear Chemistry' 2 and the '7th Nuclear and Radiochemistry Symposium' 3 whilst a more focused meeting dealt with the production and application of labelled compounds 4 in the oil industry. A couple of very interesting articles appeared during 2005 questioning what exactly is meant by many fundamental 'radiochemical' concepts 5 such as 'specific activity' and 'carrier-free' and indeed how the specific activities 6 of 'no-carrier-added' materials can be determined. The Proceedings of the 16th Symposium on Radiopharmaceutical Chemistry 7 covers advances made in radiopharmaceutical development and applications while the Proceedings of the Society of Nuclear Medicine 8 and the European Society of Nuclear Medicine 9 cover both radiopharmaceutical development and the application in diagnosis and therapy. A critical review has been published 10 on the application of positron emitting nuclides for use as radiopharmaceuticals.

show abstract

Section: Radionuclide Productionmentioning

confidence: 99%